Low incidence of red cell and HLA antibody formation by bone marrow transplant patients

Transfusion

Volumn 35, Issue 11, 1995, Pages 931-935

  Abou Elella A A ^b   Camarillo, T A ^b   Allen, M B ^b   Barclay, S ^b   Pierce, J A ^b   Holland, H K ^b   Wingard, J R ^b   Bray, R A ^b   Rodey, G E ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIBODY; HLA ANTIBODY;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; APLASTIC ANEMIA; ARTICLE; BREAST CANCER; ERYTHROPOIESIS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOPATHOGENESIS; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; RISK ASSESSMENT;

ADULT; ANTIBODY FORMATION; BONE MARROW TRANSPLANTATION; ERYTHROCYTES; FEMALE; HLA ANTIGENS; HUMANS; MALE;

EID: 0029551985     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1995.351196110898.x     Document Type: Article

References (30)

1. The impact of transplantation on the clinical laboratory. Experience at the University of Nebraska with bone marrow and liver transplantation
2. The role of the blood bank in transplantation
3. Effect of chemotherapy on the immune response in acute leukemia
4. Chemotherapy, immunocompetence, immuno‐suppression and prognosis in acute leukemia
5. Long‐term follow‐up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized
6. Suppression of transfusion‐related alloimmunization in intensively treated cancer patients
7. Immune response to chronic red blood cell transfusion
8. The kinetics of immune reconstitution after human marrow transplantation
9. Immunodeficiency and the role of suppressor cells after human bone marrow transplantation
10. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft‐versus‐host disease, and antithymocyte globulin treatment
11. Isoimmunization after multiple transfusions
12. Post‐transfusion alloimmunization in patients with sickle cell disease
13. Incidence of antibody formation and positive direct antiglobulin tests in a multitransfused hemodialysis population
14. Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants
15. The incidence of development of irregular red cell antibodies in patients with sickle cell anemia
16. Red cell alloantibodies produced after bone marrow transplantation
17. Red cell antibody problems in 1000 liver transplants
18. Red cell alloantibodies in patients with thalassemia
19. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood
20. Alloimmunization following blood transfusion
21. The natural history of alloimmunization to platelets
22. Alloimmunization following platelet transfusion: the absence of a dose‐response relationship
23. Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization
24. Prevention of refractoriness and HLA‐alloimmunization using filtered blood products
25. Alloimmunization after leukocyte‐depleted multiple random donor platelet transfusions
26. Systematic use of leukocyte‐free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer
27. Bedside filtration of blood products in the prevention of HLA alloimmunization—a prospective randomized study. Alloimmunisation Study Group
28. Blood product support in patients undergoing chemotherapy and autologous or allogeneic bone marrow transplantation for haematological malignancies
29. Blood transfusion in marrow graft recipients